C.R. Bard Inc. (NYSE:BCR) VP Betty D. Larson sold 4,032 shares of C.R. Bard stock in a transaction on Monday, September 19th. The stock was sold at an average price of $225.33, for a total transaction of $908,530.56. Following the transaction, the vice president now directly owns 10,298 shares of the company’s stock, valued at $2,320,448.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
C.R. Bard Inc. (NYSE:BCR) opened at 231.35 on Friday. The company has a market capitalization of $16.99 billion, a P/E ratio of 53.80 and a beta of 0.57. C.R. Bard Inc. has a one year low of $172.21 and a one year high of $239.43. The firm has a 50-day moving average of $220.70 and a 200-day moving average of $217.79.
C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Tuesday, July 26th. The company reported $2.54 earnings per share for the quarter, topping analysts’ consensus estimates of $2.47 by $0.07. The business earned $931.50 million during the quarter, compared to analysts’ expectations of $915.22 million. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. The company’s revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.27 EPS. On average, analysts anticipate that C.R. Bard Inc. will post $10.17 earnings per share for the current year.
Several research analysts have commented on the stock. Wells Fargo & Co. raised shares of C.R. Bard from a “market perform” rating to an “outperform” rating in a research note on Friday, September 16th. Evercore ISI assumed coverage on shares of C.R. Bard in a research note on Thursday, September 15th. They set a “buy” rating and a $235.00 price objective for the company. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Morgan Stanley reaffirmed a “hold” rating and set a $240.00 price objective on shares of C.R. Bard in a research note on Thursday, July 28th. Finally, Leerink Swann reaffirmed a “market perform” rating and set a $233.00 price objective (down from $240.00) on shares of C.R. Bard in a research note on Thursday, July 28th. Thirteen equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $233.00.
Several institutional investors have recently added to or reduced their stakes in the company. Standard Life Investments LTD acquired a new position in C.R. Bard during the second quarter worth $241,642,000. Norges Bank acquired a new position in C.R. Bard during the fourth quarter worth $123,663,000. JPMorgan Chase & Co. boosted its position in C.R. Bard by 353.4% in the first quarter. JPMorgan Chase & Co. now owns 667,533 shares of the company’s stock worth $135,290,000 after buying an additional 520,319 shares in the last quarter. Fundsmith LLP boosted its position in C.R. Bard by 24.7% in the second quarter. Fundsmith LLP now owns 2,197,626 shares of the company’s stock worth $516,220,000 after buying an additional 435,595 shares in the last quarter. Finally, Bank of Montreal Can acquired a new position in C.R. Bard during the second quarter worth $96,292,000. Institutional investors and hedge funds own 87.90% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.